CN114668687B - 一种治疗痤疮的组合物及其应用 - Google Patents
一种治疗痤疮的组合物及其应用 Download PDFInfo
- Publication number
- CN114668687B CN114668687B CN202210266710.3A CN202210266710A CN114668687B CN 114668687 B CN114668687 B CN 114668687B CN 202210266710 A CN202210266710 A CN 202210266710A CN 114668687 B CN114668687 B CN 114668687B
- Authority
- CN
- China
- Prior art keywords
- parts
- acne
- composition
- treating acne
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 62
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 22
- CFXSFDXXYYHZFU-UHFFFAOYSA-N 2-hydroxybenzoic acid;2-(trimethylazaniumyl)acetate Chemical compound C[N+](C)(C)CC(O)=O.OC(=O)C1=CC=CC=C1[O-] CFXSFDXXYYHZFU-UHFFFAOYSA-N 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940041488 betaine salicylate Drugs 0.000 claims abstract description 18
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 18
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims abstract description 17
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims abstract description 17
- 229940033329 phytosphingosine Drugs 0.000 claims abstract description 17
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 17
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 17
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 16
- 229920000615 alginic acid Polymers 0.000 claims abstract description 16
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 16
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000036542 oxidative stress Effects 0.000 abstract description 4
- -1 pi Aoning Chemical compound 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 239000000686 essence Substances 0.000 description 14
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 14
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229940055019 propionibacterium acne Drugs 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000020154 Acnes Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 241000907663 Siproeta stelenes Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8188—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗痤疮的组合物及其应用，所述的治疗痤疮的组合物，包括以下质量份的组分：0.5~3份甜菜碱水杨酸盐、1~5份琥珀酸、0.5~2份维生素B6、0.001~0.05份皮傲宁、0.01~0.04份植物鞘氨醇、0.1~0.8份水解藻胶。本发明通过将甜菜碱水杨酸盐、琥珀酸、维生素B6、皮傲宁、植物鞘氨醇、水解藻胶按照上述质量份进行配比，多种组分针对不同的靶点，全方位治疗痤疮，降低痤疮发病和氧化应激反应，有效的抑制痤疮、炎症反应，实现协同增效的效果。
Description
技术领域
本发明涉及一种治疗痤疮的组合物及其应用。
背景技术
痤疮，俗称青春痘，是一种毛囊皮脂腺的慢性炎症性皮肤病，多发于青少年人群，常见于面部，临床表现有粉刺、炎性丘疹、脓疱、结节与囊肿等皮损形态。痤疮发生的最主要机制为：皮脂分泌旺盛、毛囊皮脂腺导管角化过度与堵塞、痤疮丙酸杆菌为主的微生物感染、炎症反应等，此外，也常常发生色素沉着与皮肤屏障受损现象。
目前，防治痤疮产品的作用机理也要重点从以下几个方面考虑：（1）抑制皮脂分泌；（2）改善毛囊皮脂腺导管角化；（3）抑制痤疮丙酸杆菌等病原微生物；（4）抗炎以减轻炎性反应；（5）减轻色素沉着；（6）保湿与修护皮肤屏障。通常外用产品是防治痤疮的重要方法，目前，常用类别如下：1.维A酸类，代表性产品如：维A酸乳膏、阿达帕林凝胶、他扎罗汀凝胶等。这类药物的主要作用机理为抑制皮脂分泌、改善毛囊皮脂腺导管角化，虽然有良好的临床效果，但有以下弊端：（1）皮肤刺激性与角质剥脱性较强，大批敏感肤质人群无法耐受而不能使用；（2）破坏皮肤屏障，不利于从根本上恢复健康肤质，所以，不能长期使用以防治痤疮发生；（3）有一定致畸与光敏等毒副作用，国家法律禁止用于护肤品；（4）作用不够全面。2.过氧化苯甲酰凝胶，为过氧化物，外用后可缓慢释放出新生态氧和苯甲酸，具有抑制痤疮丙酸杆菌、抗粉刺作用，主要弊端有：（1）具有较强的皮肤刺激性，敏感肤质人群无法耐受而不能使用；（2）有一定致癌性等毒副作用，不宜长期使用，国家法律禁止用于护肤品；（3）作用不够全面。3.抗生素类，代表性产品如：克林霉素甲硝唑擦剂、夫西地酸乳膏等。这类物质的主要作用机理是抑制痤疮丙酸杆菌等病原微生物，对炎性丘疹为主的痤疮临床效果良好，但主要弊端如下：（1）长期使用，可造成抗生素耐药现象；（2）国家法律禁止用于护肤品；（3）作用不够全面。4.中药类，防治痤疮的中药外用配方虽然多如牛毛，或许有一定效果，但主要弊端如下：（1）中药成分复杂、毒副作用尚不明确，作为护肤品长期使用存在一定未知风险；（2）中药的作用机理不明确、临床效果不确定，很难让大多数痤疮人群对其效果满意。5.其他祛痘护肤品。
因此，如何提供一种具有良好安全性的治疗痤疮的产品成为了本领域技术人员亟待解决的技术问题。
发明内容
本发明的目的在于克服现有技术存在的不足之处而提供一种治疗痤疮的组合物及其应用，所述的组合物具有良好的治疗痤疮的效果，且具有良好的安全性。
为实现上述目的，本发明采取的技术方案为：
一种治疗痤疮的组合物，包括以下质量份的组分：0.5~3份甜菜碱水杨酸盐、1~5份琥珀酸、0.5~2份维生素B6、0.001~0.05份皮傲宁、0.01~0.04份植物鞘氨醇、0.1~0.8份水解藻胶。
甜菜碱水杨酸盐：甜菜碱与水杨酸主要以氢键等弱相互作用结合在一起，是典型的共晶化合物；在空间结构上，水杨酸分子上的羧基能够与甜菜碱上的N、O形成氢键，其中甜菜碱上的N作为氢键的受体，水杨酸一端羧基中的-OH作为氢键的给体形成了O-H…N氢键。分子中剩余的氢原子通过π-π堆积作用，自发呈现出并行排列有规律的稳定三维立体结构。在不需要外力作用的状态下，分子与分子之间能够通过内部氢键、π-π堆积等弱相互作用，自发的聚合、识别、组成结构稳定的超分子共晶化合物；所以甜菜碱水杨酸盐有水杨酸和甜菜碱的功效特性，兼具水杨酸和甜菜碱的功能，提供温和的去角质和抗菌功效同时具有很强的滋润和抗刺激等功效。
琥珀酸：一种二羧酸，天然存在于植物中，具有抑制细菌繁殖、去角质、调节皮脂的功效。
维生素B6：即吡哆素盐酸盐（PYRIDOXINE HCL），可降低毛细血管壁通透性及透明质酸酶活性，降低变态反应、炎症反应，促进上皮细胞生长。用于神经性皮炎、湿疹、荨麻疹、光敏性鼻炎、皮肤瘙痒症、妊娠痒症及其他妊娠性皮肤病、唇炎、痤疮、酒渣鼻、脂溢性皮炎等，对口腔溃疡、斑秃、银屑病等亦有一定疗效。抗氧化特性，在（光）氧化应激期间，可高效地清除单线态分子氧（1O2），从而起到抗光敏化、抗氧化剂、预防脂质过氧化的作用。
皮傲宁：即季铵盐-73，具有极强的抗菌活性，对细菌、葡萄球菌、大肠杆菌等有极强的杀灭能力，能够快速祛痘，对痤疮丙酸杆菌有很好的抑菌效果，也是封闭性粉刺的克星。
植物鞘氨醇：神经酰胺的前体，同时也是皮肤脂质成分之一，具有天然的修复屏障功能。其还具有强大的抑制微生物活性的作用，可抑制痤疮杆菌、金黄色葡萄球菌、马拉色菌等有害微生物。通过抑制前列腺素的合成，有效抗炎祛红。
水解藻胶：促进角质形成细胞的分化，促进伤口愈合。
本发明的发明人在大量的研究中发现，通过将甜菜碱水杨酸盐、琥珀酸、维生素B6、皮傲宁、植物鞘氨醇、水解藻胶按照上述质量份进行配比，多种组分针对不同的靶点，全方位治疗痤疮，降低痤疮发病和氧化应激反应，有效的抑制痤疮、炎症反应，实现协同增效的效果，同时所述的治疗痤疮的组合物具有良好的稳定性以及安全性。
作为本发明的优选实施方案，所述治疗痤疮的组合物包括以下质量份的组分：1~1.8份甜菜碱水杨酸盐、1.5~2.5份琥珀酸、1~1.5份维生素B6、0.005~0.04份皮傲宁、0.01~0.03份植物鞘氨醇、0.3~0.6份水解藻胶。尤其是将上述原料控制在上述质量范围内时，治疗痤疮效果更好。
作为本发明的优选实施方案，所述治疗痤疮的组合物包括以下质量份的组分：1份甜菜碱水杨酸盐、2份琥珀酸、1.2份维生素B6、0.01份皮傲宁、0.02份植物鞘氨醇、0.5份水解藻胶。尤其是将上述原料控制在上述质量范围内时，治疗痤疮效果最好。
本发明还提供了精华液，包括上述所述的治疗痤疮的组合物。
作为本发明的优选实施方案，所述精华液中治疗痤疮的组合物的质量百分含量为4~20%。
作为本发明的优选实施方案，所述精华液还包括以下质量百分含量的组分：0.03~0.08%EDTA-2Na、4~6%丁二醇、2~4%山梨醇、0.2~0.4%黄原胶、1.5~2.5%玉米淀粉、1.2~1.8%聚丙烯酸酯交联聚合物-6、0.04~0.06%苯氧乙醇、0.36~0.54%乙基己基甘油、余量去离子水。
本发明还提供了一种精华液的制备方法，包括以下步骤：
（1）将治疗痤疮的组合物用部分去离子水预混，得到预混物；
（2）将EDTA-2Na、丁二醇、山梨醇、黄原胶、玉米淀粉、聚丙烯酸酯交联聚合物-6加入到另外一部分去离子水中，在70~90℃下混合均匀，得到水溶液；
（3）将水溶液降温至30~45℃，加入预混物、苯氧乙醇、乙基己基甘油，混合均匀，即得所述的精华液。
本发明的有益效果在于：本发明通过将甜菜碱水杨酸盐、琥珀酸、维生素B6、皮傲宁、植物鞘氨醇、水解藻胶多种活性成分在特定的质量份配比下进行组合，多种组分针对不同的靶点，全方位治疗痤疮，降低痤疮发病和氧化应激反应，有效的抑制痤疮、炎症反应，实现协同增效的效果。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚，下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
具体的分散、搅拌处理方式没有特别限制。
实施例1
一种治疗痤疮的组合物，包括以下质量份的组分：0.5份甜菜碱水杨酸盐、5份琥珀酸、0.5份维生素B6、0.05份皮傲宁、0.01份植物鞘氨醇、0.8份水解藻胶。
实施例2
一种治疗痤疮的组合物，包括以下质量份的组分：3份甜菜碱水杨酸盐、1份琥珀酸、2份维生素B6、0.001份皮傲宁、0.04份植物鞘氨醇、0.1份水解藻胶。
实施例3
一种治疗痤疮的组合物，包括以下质量份的组分：1份甜菜碱水杨酸盐、2.5份琥珀酸、1份维生素B6、0.04份皮傲宁、0.01份植物鞘氨醇、0.6份水解藻胶。
实施例4
一种治疗痤疮的组合物，包括以下质量份的组分：1.8份甜菜碱水杨酸盐、1.5份琥珀酸、1.5份维生素B6、0.005份皮傲宁、0.03份植物鞘氨醇、0.3份水解藻胶。
实施例5
一种治疗痤疮的组合物，包括以下质量份的组分：1份甜菜碱水杨酸盐、2份琥珀酸、1.2份维生素B6、0.01份皮傲宁、0.02份植物鞘氨醇、0.5份水解藻胶。
实施例6~10为本发明所述的的精华液，其配方如表1所示，其中，实施例6~10所述的精华液分别包含实施例1~5所述的治疗痤疮的组合物，且实施例6~10所述的精华液的制备方法相同，均包括以下步骤：
（1）将治疗痤疮的组合物用部分去离子水预混，得到预混物；
（2）将EDTA-2Na、丁二醇、山梨醇、黄原胶、玉米淀粉、聚丙烯酸酯交联聚合物-6加入到另外一部分去离子水中，在80℃下混合均匀，得到水溶液；
（3）将水溶液降温至40℃，加入预混物、苯氧乙醇、乙基己基甘油，混合均匀，即得所述的精华液。
表1 实施例6~10所述的精华液的配方表（表中为质量百分数%）
表2对比例1~7所述的精华液的配方表（表中为质量百分数%）
为了进一步证明本发明的效果，提供了以下测试方法：
1.稳定性测试
对实施例6~10及对比例1~7进行稳定性测试，耐热性测试为在45±2℃条件下静置一个月，观察其外观、颜色和气味；耐寒性测试为在-18±2℃条件下静置一个月，观察其外观、颜色和气味；冷热循环性测试为在45℃、常温和-18℃各存放24h，循环3次，观察其外观、颜色和气味。测试结果如表3所示。
表3 稳定性测试结果
2.痤疮消退时间测试
（1）志愿者筛选：选择60位志愿者，将所有志愿者按每组5人随机分成12组，各组志愿者分别试用实施例6～10、对比例1～7所述的精华液。
纳入志愿者标准为：年龄20～45岁，性别不限；油性、混合性肌肤，脸部有痘痘人群；近一月内未曾使用激素类药物及免疫抑制剂者；现在或近30天内受试部位未参加其他临床试验者；能很好配合试验者；能够阅读和理解知情同意书的所有内容，并自愿签署知情同意书；试验期间同意不使用任何对结果有影响的化妆品、药物和保健品。
排除标准：痤疮患处有开放性伤口或糜烂面者；高度过敏体质者；有化妆品过敏史者；妊娠、哺乳或在测试期间打算怀孕的女性者；有严重心、肝、肾功能损害及严重免疫功能低下者；有精神疾病、严重内分泌疾病者以及口服避孕药者；30天内参加药物临床试验者或其它试验者，或近1周内有系统用对试验结果有影响的药物者；2周内有口服和外用可能对试验结果有影响的美容产品者；研究者认为不适于参加本项测试。
中止及退出标准：在试验期间未按测试要求进行涂抹受试样品或未按要求进行回访记录；使用期间患有严重疾病或发生严重不良反应。
（2）测试方法：志愿者每日早晚洁面后，全脸使用上述产品2小时后，拍照记录痤疮的消退时间（痤疮消退时间即痤疮由大变小到结痂或体积不再变小的时间），每组取平均值，记录如下表4所示。
3. 抑菌测试：
测试方法：GB15979-2002《一次性使用卫生用品卫生标准》附录C4“溶出性抗(抑)菌产品抑菌性能试验方法。
根据上述测试方法，首先取痤疮丙酸杆菌24h培养物，并用0.03mol/L磷酸盐缓冲液洗后，制成105CFU/ml菌悬液，然后分别取1g实施例6~10和对比例1~7的样品加入菌悬液0.1ml均匀涂布混合，20min后加入9mL 0 .03mol/L磷酸盐缓冲液充分混匀，做适当稀释后，取其中3个稀释度，分别取1mL置于两个平行平皿中，再加入相应培养基在36±1℃厌氧条件下培养24小时，作菌落计数。以上试验重复3次，取平均数，设置空白对照组。
抑菌率的计算公式为：X＝(A-B)/A×100％，其中X为抑菌率，A为对照样品平均回收菌落，B为试验样品平均回收菌落，测试结果见表4。
表4 测试结果
从表4可看出，由本发明所述的治疗痤疮的组合物制备而成的精华液具有良好的治疗痤疮效果。
对比实施例6~10可看出，不同的治疗痤疮的组合物的原料配比能够影响到精华液的治疗痤疮效果，其中实施例10为最佳配比，具有最佳的治疗痤疮的效果。
对比实施例10与对比例1~7可知，本发明所述的治疗痤疮的组合物中的甜菜碱水杨酸盐、琥珀酸、维生素B6、皮傲宁、植物鞘氨醇、水解藻胶联用在治疗痤疮方面具有显著的协同增效作用。
最后所应当说明的是，以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。
Claims (4)
1.一种精华液，其特征在于，所述精华液包括以下质量百分含量的组分：4～20％治疗痤疮的组合物、0.03～0.08％EDTA-2Na、4～6％丁二醇、2～4％山梨醇、0.2～0.4％黄原胶、1.5～2.5％玉米淀粉、1.2～1.8％聚丙烯酸酯交联聚合物-6、0.04～0.06％苯氧乙醇、0.36～0.54％乙基己基甘油、余量去离子水；
所述治疗痤疮的组合物由以下质量份的组分组成：0.5～3份甜菜碱水杨酸盐、1～5份琥珀酸、0.5～2份维生素B6、0.001～0.05份皮傲宁、0.01～0.04份植物鞘氨醇、0.1～0.8份水解藻胶。
2.根据权利要求1所述的精华液，其特征在于，所述的治疗痤疮的组合物由以下质量份的组分组成：1～1.8份甜菜碱水杨酸盐、1.5～2.5份琥珀酸、1～1.5份维生素B6、0.005～0.04份皮傲宁、0.01～0.03份植物鞘氨醇、0.3～0.6份水解藻胶。
3.根据权利要求1所述的精华液，其特征在于，所述的治疗痤疮的组合物由以下质量份的组分组成：1份甜菜碱水杨酸盐、2份琥珀酸、1.2份维生素B6、0.01份皮傲宁、0.02份植物鞘氨醇、0.5份水解藻胶。
4.如权利要求1～3任一所述的精华液的制备方法，其特征在于，包括以下步骤：
(1)将治疗痤疮的组合物用部分去离子水预混，得到预混物；
(2)将EDTA-2Na、丁二醇、山梨醇、黄原胶、玉米淀粉、聚丙烯酸酯交联聚合物-6加入到另外一部分去离子水中，在70～90℃下混合均匀，得到水溶液；
(3)将水溶液降温至30～45℃，加入预混物、苯氧乙醇、乙基己基甘油，混合均匀，即得所述的精华液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210266710.3A CN114668687B (zh) | 2022-03-17 | 2022-03-17 | 一种治疗痤疮的组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210266710.3A CN114668687B (zh) | 2022-03-17 | 2022-03-17 | 一种治疗痤疮的组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114668687A CN114668687A (zh) | 2022-06-28 |
| CN114668687B true CN114668687B (zh) | 2024-03-29 |
Family
ID=82075125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210266710.3A Active CN114668687B (zh) | 2022-03-17 | 2022-03-17 | 一种治疗痤疮的组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114668687B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116370325A (zh) * | 2023-03-23 | 2023-07-04 | 上海科黛生物科技有限公司 | 一种透明壬二酸凝胶及其制备方法和应用 |
| CN116407478A (zh) * | 2023-05-11 | 2023-07-11 | 杭州以息互联网科技有限公司 | 一种温和的祛痘组合物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2443388A (en) * | 2006-10-30 | 2008-05-07 | Reckitt & Colmann Prod Ltd | Acne treatment |
| CN106580822A (zh) * | 2016-12-16 | 2017-04-26 | 华南协同创新研究院 | 一种植物祛痘复合物及其制备方法与应用 |
| CN108310098A (zh) * | 2018-04-13 | 2018-07-24 | 覃静欣 | 一种治疗痤疮的组合药物及其制备方法 |
| CN110772465A (zh) * | 2019-12-17 | 2020-02-11 | 厦门泽本健康管理有限公司 | 一种祛痘印组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4153127A1 (en) * | 2020-05-19 | 2023-03-29 | L'oreal | Anti-acne compositions |
-
2022
- 2022-03-17 CN CN202210266710.3A patent/CN114668687B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2443388A (en) * | 2006-10-30 | 2008-05-07 | Reckitt & Colmann Prod Ltd | Acne treatment |
| CN106580822A (zh) * | 2016-12-16 | 2017-04-26 | 华南协同创新研究院 | 一种植物祛痘复合物及其制备方法与应用 |
| CN108310098A (zh) * | 2018-04-13 | 2018-07-24 | 覃静欣 | 一种治疗痤疮的组合药物及其制备方法 |
| CN110772465A (zh) * | 2019-12-17 | 2020-02-11 | 厦门泽本健康管理有限公司 | 一种祛痘印组合物 |
Non-Patent Citations (1)
| Title |
|---|
| 肖海鹏.《CDR临床用药手册》.中国医药科技出版社,2020,(第1版),1798. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114668687A (zh) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114668687B (zh) | 一种治疗痤疮的组合物及其应用 | |
| US8679552B2 (en) | Acne vulgaris treatment regimen | |
| US5696169A (en) | Antibacterial and antifungal activity method, therapeutic method of infectious diseases and preserving method of cosmetics | |
| RU2408372C2 (ru) | Применение октенидина дигидрохлорида в полутвердых препаратах | |
| AU2002367451B2 (en) | Composition based on ethyl ester of linoleic acid and triethyl ester of citric acid for topical use in the treatment of seborrhoea and acne | |
| WO1993017559A1 (en) | Method of treating infectious disease, method of preventing putrefaction of cosmetic, and antibacterial/antifungal agent and cosmetic | |
| WO2012015487A1 (en) | Combination of dapsone with adapalene | |
| CA2769640A1 (en) | Combination of dapsone with adapalene | |
| TW201330856A (zh) | 廣效性的天然防腐組成物 | |
| AU777629B2 (en) | Use of retinoid-type compounds as antibacterial agents | |
| KR20120058850A (ko) | 항염증 및 항균활성을 가지는 조성물 | |
| CN113456570A (zh) | 一种祛痘组合物、祛痘啫喱及其制备方法 | |
| US20130039995A1 (en) | Dermatological compositions comprising at least one reinoid compound, an anti-irritant compound and benzoyl peroxide | |
| CN1210041C (zh) | 治疗痤疮的复方外用药物 | |
| KR20060092333A (ko) | 생귀나린을 함유하는 여드름 치료용 화장료 조성물 | |
| CN116172888A (zh) | 用于调节肌肤微生态的含氨基酸衍生物的组合物 | |
| TW201034658A (en) | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases | |
| CN1528326A (zh) | 主治痤疮的复方外用药物 | |
| JP2005206521A (ja) | 抗菌剤 | |
| GB2216793A (en) | Treatment or prophylaxis of acne, dandruff or related conditions | |
| Faergemann et al. | Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol | |
| JPH0753369A (ja) | 外用殺菌方法 | |
| JPH03157311A (ja) | にきび用化粧料 | |
| US20110305747A1 (en) | Combination of dapsone with other anti-acne agents | |
| KR20180135169A (ko) | 퀘르세틴 및 비타민 d를 함유하는 여드름 피부 개선용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |